Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Jette, Belgium.
Breast J. 2019 Jul;25(4):663-666. doi: 10.1111/tbj.13306. Epub 2019 May 9.
Adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) is adopted worldwide as a valuable option for elderly patients with high-risk early breast cancer. Some studies suggest that paclitaxel may have a better therapeutic ratio than docetaxel. Therefore we have implemented an adjuvant chemotherapy in which docetaxel was replaced by paclitaxel. We report here the retrospective analysis of that cohort and make a safety comparison with an earlier TC cohort in the same target population. This retrospective analysis demonstrates the feasibility of paclitaxel/cyclophosphamide as an alternative, better tolerated adjuvant regimen for elderly patients. Further evaluation and assessment of noninferiority to TC is warranted.
紫杉类/环磷酰胺（TC）辅助化疗作为一种有价值的治疗方案，被广泛应用于伴有高危因素的老年早期乳腺癌患者。一些研究表明，紫杉醇的治疗效果可能优于多西他赛。因此，我们采用了多西他赛替代紫杉醇的辅助化疗方案。本研究回顾性分析了该队列，并且与同一目标人群中较早的 TC 队列进行了安全性比较。本回顾性分析证明了紫杉醇/环磷酰胺作为一种替代方案的可行性，对于老年患者而言，该方案具有更好的耐受性。进一步的评估和非劣效性检验是必要的。
